Sugi Predict

Sugi Predict / Compounds / SCHEMBL9892949

SCHEMBL9892949

SCHEMBL9892949

CCOP(C)(=O)Cc1cnc(NC(=O)OC(C)(C)C)cn1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 5/20 0.38
▸ GCK P35557 1/20 0.37
▸ GSK3B P49841 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ HDAC1 Q13547 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ NAMPT P43490 2/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ CYP17A1 P05093 1/20 0.32
▸ ATR Q13535 1/20 0.32
▸ SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140072 0.90 GCK (0.43) MAPKAPK2GCKGSK3BDYRK1AHDAC1
SCHEMBL1107423 0.80 GSK3B (0.38) MAPKAPK2GCKGSK3BDYRK1AHDAC1
SCHEMBL9897762 0.79 GSK3B (0.40) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL13323075 0.79 GSK3B (0.41) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL7452419 0.78 MAPKAPK2 (0.42) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL611654 0.78 GSK3B (0.40) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL2668927 0.78 GSK3B (0.40) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL29934934 0.78 GSK3B (0.40) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL27886524 0.78 MAPKAPK2 (0.40) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT
SCHEMBL19053692 0.77 MAPKAPK2 (0.42) MAPKAPK2GSK3BDYRK1AHDAC1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 — — US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 — — US disclosed
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 — — US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 — — US disclosed
US-7910747-B2 Phosphonate and phosphinate pyrazolylamide glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 — — US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118211-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, MPO, GCK MAPKAPK2 158/4885GCK 3/4885GSK3B 1927/4885
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 MAPKAPK2 142/4885GCK 2/4885GSK3B 1324/4885
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 MAPKAPK2 115/4885GCK 2/4885GSK3B 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.